Drug Approval | September 01, 2022
Biological E. announces CDSCO recommendation of its infant’s vaccine
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India
The Subject Expert Committee has recommended grant of permission to conduct Phase 3 trials under certain conditions
Support from DFC will help produce one billion vaccine doses by the end of 2022
The trial will be conducted across 10 sites in India
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
Subscribe To Our Newsletter & Stay Updated
